Oppenheimer raises Harmony Biosciences stock price target on patent strength

Oppenheimer raised Harmony Biosciences’ price target to $72 from $62 and kept an Outperform rating, citing progress on settling with six of seven generic filers and continued confidence in Wakix exclusivity into 2030. The company also reported Q4 2025 Wakix sales of $243.8 million, up 1.8% sequentially, while management added new CFO and COO leadership. UBS lowered its target to $36 and Truist reiterated Hold at $25, so the setup remains constructive but mixed.

Analysis

HRMY looks less like a simple “patent-risk reduced” story and more like a duration extension trade. If management can keep the generic threat pushed into 2029-2030, the market should start underwriting a multi-year cash flow runway, which is exactly what low-teens earnings multiples miss: the equity is being priced off a near-expiry binary that may no longer exist. The bigger second-order effect is that every incremental settlement also weakens the negotiating leverage of the last holdout, so the final economics of the litigation settlement may be less important than the signaling value that the franchise is now defensible into the next capital allocation cycle.

The core risk is not the legal endpoint; it is whether the market becomes overconfident on longevity while ignoring product concentration. A single-brand asset can re-rate hard on patent clarity, but that same rerating makes the stock vulnerable to any miss in growth cadence, payer pressure, or weak execution in the pipeline readouts expected over the next 12-18 months. In other words, the near-term catalyst path is favorable, but the earnings bridge remains narrow until the next indication can be shown to de-risk post-Wakix cash generation.

A more interesting contrarian angle is that the street may be underestimating how quickly the sell-side can move from “LOE overhang” to “capital return story.” If generic entry slips meaningfully, a mid-cap biotech with improving legal visibility, CFO/COO changes, and modest valuation can become an M&A or special-situation candidate before it becomes a pure growth compounder. That makes the asymmetry attractive: upside comes from multiple expansion plus timeline extension, while downside is mostly if the settlement framework is less durable than implied or pipeline catalysts disappoint.

Key Decisions for Investors

• Long HRMY vs short XBI for 3-6 months: own the idiosyncratic patent-duration re-rating while hedging away sector beta; this is cleaner than a standalone long if biotech risk appetite fades.
• Buy HRMY calls or call spreads with 6-12 month tenor: best expression if you expect the market to reprice the generic launch window further out; the convexity is strongest before the next litigation or clinical datapoint.
• If already long, trim into strength only after the next catalyst window, not immediately: the stock is vulnerable to a classic multiple/expectations reset if investors front-run settlement news too aggressively.
• Watch for a pair trade versus a weaker single-asset biotech with similar valuation but no duration extension: HRMY should outperform on any evidence that LOE timing remains pushed out, but the trade should be exited if pipeline data fail to diversify the story.
• Do not short on headline legal relief alone; wait for evidence of post-settlement downside in estimates or a failed catalyst, because the short thesis becomes crowded once the market accepts 2029-2030 exclusivity.